Literature DB >> 21217443

Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2.

Jeffrey B Knox1, Joseph M Dai, Joseph Orchowski.   

Abstract

STUDY DESIGN.: Retrospective radiographic review. OBJECTIVE.: To determine the incidence of osteolysis, graft subsidence, and cage migration after recombinant human bone morphogenetic protein-2 (rhBMP-2) use with transforaminal lumbar interbody fusion (TLIF). SUMMARY OF BACKGROUND DATA.: Osteolysis after TLIF is a recently described phenomenon associated with rhBMP-2 use. Although this is typically a self-limiting condition, complications such as graft subsidence and cage migration have been described. The incidence of this is not well defined and most studies use plain radiographs for diagnosis rather than more advanced imaging. This study serves to quantify the risk of osteolysis and its associated graft complications with routine use of computed tomography. METHODS.: A total of 58 patients who underwent primary TLIF from a single surgeon between 2004 and 2007 underwent routine postoperative computed tomographic scan. Seventy-seven levels of fusion were evaluated for osteolysis. All patients received the same dose of rhBMP-2 of 5 mg per level. Imaging was performed immediately postoperative and again at an average of 4.3 months postoperative (range = 2.4-9.0 months). These images were evaluated for the presence of osteolysis, graft subsidence, and cage migration. These changes were then graded according to their severity. RESULTS.: Osteolysis was found in 16 of the 58 (27.6%) patients and 19 of the 77 (24.7%) levels treated. No significant difference was found between single and two-level fusions. The degree of osteolysis ranged from 3 to 20 mm with an average of 12.5 mm. The osteolysis was characterized as severe (>1 cm) in 12 of the 19 levels. Of the patients with osteolysis, 31.6% demonstrated graft subsidence all of which occurred with severe osteolytic defects. Migration of the intervertebral cage was found in 8.8% of patients. CONCLUSION.: rhBMP-2 use with TLIF is associated with a significant risk of postoperative osteolysis. Patients who demonstrated postoperative osteolysis were associated with significant risk of subsidence or migration of the intervertebral cage. The clinical implications of these changes are not currently known.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217443     DOI: 10.1097/BRS.0b013e3181e030e0

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  9 in total

1.  PEEK versus metal cages in posterior lumbar interbody fusion: a clinical and radiological comparative study.

Authors:  F Cuzzocrea; A Ivone; E Jannelli; A Fioruzzi; E Ferranti; R Vanelli; F Benazzo
Journal:  Musculoskelet Surg       Date:  2018-12-10

2.  Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion.

Authors:  Hsin Chuan Pan; Soonchul Lee; Kang Ting; Jia Shen; Chenchao Wang; Alan Nguyen; Emily A Berthiaume; Janette N Zara; A Simon Turner; Howard B Seim; Jin Hee Kwak; Xinli Zhang; Chia Soo
Journal:  Am J Pathol       Date:  2017-05-11       Impact factor: 4.307

3.  An analysis of fusion cage migration in unilateral and bilateral fixation with transforaminal lumbar interbody fusion.

Authors:  Jan William Duncan; Richard Anthony Bailey
Journal:  Eur Spine J       Date:  2012-08-10       Impact factor: 3.134

Review 4.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

5.  Comparison of unilateral versus bilateral pedicle screw fixation with cage fusion in degenerative lumbar diseases: a meta-analysis.

Authors:  Shan-Wen Xiao; Hua Jiang; Li-Jing Yang; Zeng-Ming Xiao
Journal:  Eur Spine J       Date:  2014-12-16       Impact factor: 3.134

6.  Bone Morphogenetic Protein in Anterior Lumbar Interbody Fusions: A Propensity-Matched Medicare Outcome Analysis.

Authors:  Syed I Khalid; Ravi S Nunna; Rachyl M Shanker; Kyle B Thomson; Rown Parola; Owoicho Adogwa; Ankit I Mehta
Journal:  Int J Spine Surg       Date:  2022-06-14

7.  Comparison of fusion rates following transforaminal lumbar interbody fusion using polyetheretherketone cages or titanium cages with transpedicular instrumentation.

Authors:  Osamu Nemoto; Takashi Asazuma; Yoshiyuki Yato; Hideaki Imabayashi; Hiroki Yasuoka; Akira Fujikawa
Journal:  Eur Spine J       Date:  2014-07-12       Impact factor: 3.134

8.  The effects of a single intravenous injection of novel activin A/BMP-2 (AB204) on toxicity and the respiratory and central nervous systems.

Authors:  Byung-Hak Yoon; Jae Hyup Lee; Kyuheum Na; Chihoon Ahn; Jongho Cho; Hyun Chan Ahn; Jungyoun Choi; Hyosun Oh; Byong Moon Kim; Senyon Choe
Journal:  Drug Chem Toxicol       Date:  2015-10-07       Impact factor: 3.356

9.  Transforaminal lumbar interbody fusion rates in patients using a novel titanium implant and demineralized cancellous allograft bone sponge.

Authors:  Gerard Girasole; Gerard Muro; Abraham Mintz; Jason Chertoff
Journal:  Int J Spine Surg       Date:  2013-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.